What are the indications of CES therapy for depression?
- Fatigue
- Oversleeping or insomnia
- Persistent sadness,anxiety
- Feelings of wrothlessness
- Long term concerns
- Repeated panic attacks
- Depressive
What's the technical parameter of the COZING-IN02?
|
Model Number: |
COZING-IN02 |
|
Instrument classification: |
Class II |
|
Pulse repetition frequcncy: |
1-999Hz |
|
Built-in lithiun battery voltage: |
3.7 -4.2V |
|
Timer |
5-60mins |
What are the advantages of CES therapy for depression?
①Customizable Frequency: 1-999Hz.
②Lock Function: to avoid accidental touches.
③Touchscreen : Easy to operation.
④Adjustable Intensity: 10 levels of intensity options.
⑤Timer Options: Choose from 10 different timer settings.
⑥Dual Therapy: Combines Earlobe and 650nm earphone
⑦USB-C Port
⑧Customization: wavelength, intensity, color and package from 100 pieces, supporting OEM and ODM.
How CES Therapy Works for Depression?
Neurochemical Regulation
The therapy delivers microcurrent pulses (typically 0.5-100Hz) through electrodes placed on the head
These signals stimulate the hypothalamus and limbic system
This stimulation helps normalize production of key neurotransmitters:
• Serotonin (mood regulation)
• Dopamine (pleasure/reward)
• GABA (calming effect)
• Beta-endorphins (natural pain relief)
Brainwave Optimization
CES helps restore balanced electrical activity in the brain
Promotes alpha/theta wave production for relaxation
Reduces excessive beta waves associated with stress
Stress Response Modulation
Calms overactive sympathetic nervous system
Reduces cortisol (stress hormone) levels
Activates parasympathetic nervous system for relaxation
COZING-IN02 Product Display
COZING-IN02 CES therapy for depression Clinical Study:
Background:
Cranial electrotherapy stimulation (CES) represents a neurostimulation technique involving the application of alternating microcurrent via electrodes positioned on the scalp. Our study aimed to assess the efficacy of CES in mitigating stress levels.
Methods:
Participants experiencing subjective stress alongside subclinical manifestations of depression or insomnia were identified through interviews and questionnaires. They were randomly allocated to either the active CES or sham groups and instructed to utilize the device for 30 minutes twice daily over a three-week period. Evaluation encompassed psychological rating scales, quantitative electroencephalography (QEEG), and serial salivary cortisol measurements conducted pre- and post-intervention.
Results:
Sixty-two participants (comprising 58 females, mean age = 47.3 ± 8.2 years) successfully completed the trial. Following intervention, depression scores exhibited a noteworthy reduction, approaching normal levels (Beck depression inventory-II, from 31.3 ± 11.6 to 10.8 ± 7.2, p < 0.001) within the CES group, with significantly greater improvements observed compared to the sham cohort (p = 0.020). Notable group-by-visit interactions were observed in absolute delta power within the tempOral area (p = 0.033), as well as theta (p = 0.038), beta (p = 0.048), and high beta power (p = 0.048) within the parietal region. CES intervention contributed to a flattening of the cortisol slope (p = 0.011) and elevated bedtime cortisol levels (p = 0.036) relative to the sham intervention.
Limitations:
Potential bias may have been introduced during the trial process, given that device utilization and sample collection were self-administered by participants in a home setting.
Conclusions:
CES emerges as a promising adjunctive therapy for alleviating depressive symptoms and stress response, highlighting its potential utility in stress management protocols.
FAQ
